InsidersTradesSigma
Total declarations
Company
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
12
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by OLER ABRAHAM N., Vice-Président et Conseiller Général. Officer active across 1 company, notably Onconova Therapeutics, Inc.. Cumulatively, 14 disclosures have been logged. Breakdown: 12 buys · 0 sell. Total volume traded: €45k. Activity tracked since 28 September 2021. The latest transaction was filed on 28 January 2022 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations14 total
1,500 shares@ US$1.673.2% of flowCommon StockSEC:0001179110-22-000652:0
Ideal exit: 25 Oct 2022 (T+270)
1,500 shares@ US$1.673.2% of flowCommon StockSEC:0001179110-22-000652
Ideal exit: 25 Oct 2022 (T+270)
1,500 shares@ US$2.023.8% of flowCommon StockSEC:0001179110-22-000564:0
Ideal exit: 18 Oct 2022 (T+270)
1,500 shares@ US$2.023.8% of flowCommon StockSEC:0001179110-22-000564
Ideal exit: 18 Oct 2022 (T+270)
1,500 shares@ US$2.204.0% of flowCommon StockSEC:0001415889-22-000588:0
Ideal exit: 11 Oct 2022 (T+270)
1,500 shares@ US$2.204.0% of flowCommon StockSEC:0001415889-22-000588
Ideal exit: 11 Oct 2022 (T+270)
1,500 shares@ US$2.394.5% of flowCommon StockSEC:0001179110-22-000350:0
Ideal exit: 4 Oct 2022 (T+270)
1,500 shares@ US$2.394.5% of flowCommon StockSEC:0001179110-22-000350
Ideal exit: 4 Oct 2022 (T+270)
1,000 shares@ US$3.163.9% of flowCommon stockSEC:0001415889-21-005425
Ideal exit: 16 Aug 2022 (T+270)
1,000 shares@ US$3.163.9% of flowCommon stockSEC:0001415889-21-005425:0
Ideal exit: 16 Aug 2022 (T+270)
5,000 shares@ US$3.0018.6% of flowCommon StockSEC:0001179110-21-010259:0
5,000 shares@ US$3.0018.6% of flowCommon StockSEC:0001179110-21-010259
2,381 shares@ US$4.2012.0% of flowCommon StockSEC:0001179110-21-008982
Ideal exit: 25 Jun 2022 (T+270)
2,381 shares@ US$4.2012.0% of flowCommon StockSEC:0001179110-21-008982:0
Ideal exit: 25 Jun 2022 (T+270)
14 of 14 declarations
About OLER ABRAHAM N.
Abraham N. Oler serves as Senior Vice President of Corporate Development and General Counsel at Onconova Therapeutics, Inc. In this role, he oversees the legal and strategic aspects of the company, ensuring that operations comply with applicable regulations. Abraham brings valuable expertise in business law and transactions, contributing to Onconova's mission in developing innovative treatments.
